Articolo - Pharmaceutical interventions for high risk COVID-19 patients
, most pharmaceutical COVID-19 treatments have been ruled out by the emergence of new variants or are way too expensive or impractical to treat large sectors of the general population [14]. The RCTs of these COVID-19 drugs were conducted on unvaccinated high-risk COVID- 19 patients before the Omicron ...